Structure Therapeutics (GPCR) Profit After Tax (2022 - 2026)

Structure Therapeutics' Profit After Tax history runs 5 years deep, the most recent figure standing at -$3.2 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 93.06% year-over-year to -$3.2 million in Q1 2026; TTM through Mar 2026 was $44.2 million, a 140.79% increase from a year earlier, with the FY2025 full-year figure at $140000.0, up 100.11% from the prior year.
• Profit After Tax slipped to -$3.2 million in Q1 2026 per GPCR's latest filing, from $174.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at $174.3 million in Q4 2025 and bottomed at -$88.8 million in Q4 2023.
• The 5-year median for Profit After Tax is -$23.3 million (2023), against an average of -$14.4 million.
• Biggest YoY gain for Profit After Tax was 549.38% in 2025; the steepest drop was 2061.79% in 2025.
• Year by year, Profit After Tax stood at $39.5 million in 2022, then slumped by 324.95% to -$88.8 million in 2023, then jumped by 56.3% to -$38.8 million in 2024, then surged by 549.38% to $174.3 million in 2025, then plunged by 101.86% to -$3.2 million in 2026.
• Per Business Quant, the three latest GPCR Profit After Tax figures stand at -$3.2 million (Q1 2026), $174.3 million (Q4 2025), and -$65.2 million (Q3 2025).